{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:27:43Z","timestamp":1786595263016,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mianyang Key Laboratory of Anesthesia and Neuroregulation","award":["MZSJ202509"],"award-info":[{"award-number":["MZSJ202509"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Remimazolam is an ultrashort-acting benzodiazepine for procedural sedation, with rare reports of anaphylaxis. Its clinical phenotypes and management strategies for refractory cases with suboptimal adrenaline response remain poorly defined. As remimazolam use increases globally, exploring effective interventions for its induced hypersensitivity reactions is clinically important. This report presents a rare remimazolam-induced Grade III hypersensitivity reaction dominated by bronchospasm, with flumazenil administration temporally associated with improvement of adrenaline-refractory symptoms, adding a hypothesis-generating observation to the existing literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 49-year-old Han female developed a Grade III hypersensitivity reaction after remimazolam administration for gastroscopy sedation, with no prior allergic history or underlying diseases. The main symptoms included severe persistent bronchospasm (initial and dominant manifestation), facial flushing, nausea, vomiting, abdominal pain, and hemodynamic instability (peripheral oxygen saturation 83%, blood pressure 75\/53\u00a0mmHg, tachycardia). Discontinuation of remimazolam and stepwise adrenaline bolus administration failed to relieve bronchospasm effectively. Intravenous flumazenil administration, combined with an additional adrenaline dose, was temporally associated with the gradual resolution of all allergic symptoms and hemodynamic stabilization. The adrenaline dosing followed international perioperative anaphylaxis management consensus, with stepwise escalation based on the patient\u2019s clinical response and American Society of Anesthesiologists physical status I.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Remimazolam-induced hypersensitivity reactions can present as Grade III cases dominated by bronchospasm, requiring prompt clinical recognition and targeted intervention. The temporal association between flumazenil administration and relief of adrenaline-refractory bronchospasm warrants further investigation, but this observation is hypothesis-generating only; the independent therapeutic effect and mechanism of flumazenil remain unproven and require confirmation by more studies. For suspected remimazolam-induced anaphylaxis, serum tryptase measurement and convalescent allergen skin testing are recommended to confirm diagnosis and guide subsequent anesthetic selection. This single case report has inherent limitations, and clinical improvement may result from the combined effect of multiple interventions, so no definitive conclusion can be drawn regarding flumazenil's role.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06187-5","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:24:30Z","timestamp":1780989870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Possible bronchospasm relief following flumazenil administration in a remimazolam-induced Grade III hypersensitivity reaction: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9940-5746","authenticated-orcid":false,"given":"Yunfei","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9686-4869","authenticated-orcid":false,"given":"Deyou","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"6187_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-02052-w","volume":"23","author":"X Hu","year":"2023","unstructured":"Hu X, Tang Y, Fang X. Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation. BMC Anesthesiol. 2023;23: 99.","journal-title":"BMC Anesthesiol"},{"key":"6187_CR2","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000001616","volume":"16","author":"Y Hasushita","year":"2022","unstructured":"Hasushita Y, Nagao M, Miyazawa Y, Yunoki K, Mima H. Cardiac arrest following remimazolam-induced anaphylaxis: a case report. A&A Pract. 2022;16: e01616.","journal-title":"A&A Pract"},{"key":"6187_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/EJA.0000000000001794","volume":"40","author":"R Cinotti","year":"2023","unstructured":"Cinotti R. An update on remimazolam and anaphylaxis. Eur J Anesthesiol. 2023;40:153\u20134.","journal-title":"Eur J Anesthesiol"},{"key":"6187_CR4","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/all.13820","volume":"74","author":"LH Garvey","year":"2019","unstructured":"Garvey LH, Ebo DG, Mertes P-M, Dewachter P, Garcez T, Kopac P, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy. 2019;74:1872\u201384.","journal-title":"Allergy"},{"key":"6187_CR5","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.bja.2019.04.044","volume":"123","author":"LH Garvey","year":"2019","unstructured":"Garvey LH, Dewachter P, Hepner DL, Mertes PM, Voltolini S, Clarke R, et al. Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations. Br J Anesth. 2019;123:e50-64.","journal-title":"Br J Anesth"},{"key":"6187_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60060971","volume":"60","author":"J Lee","year":"2024","unstructured":"Lee J, Kim S-H. Remimazolam-induced anaphylaxis and cardiovascular collapse: a narrative systematic review of eleven cases. Medicina. 2024;60: 971.","journal-title":"Medicina"},{"key":"6187_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bja.2023.04.036","volume":"131","author":"L Savic","year":"2023","unstructured":"Savic L, Volcheck GW, Garvey LH. Treatment of perioperative anaphylaxis: room for improvement? Br J Anaesth. 2023;131:17\u20139.","journal-title":"Br J Anaesth"},{"key":"6187_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-024-02591-w","volume":"24","author":"T Nakai","year":"2024","unstructured":"Nakai T, Kako E, Ota H, So M, Sobue K. Remimazolam anaphylaxis in a patient not allergic to brotizolam: a case report and literature review. BMC Anesthesiol. 2024;24: 204.","journal-title":"BMC Anesthesiol"},{"key":"6187_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59111915","volume":"59","author":"S Lee","year":"2023","unstructured":"Lee S, Park J, Kim NH, Hong H, Sohn KH, Kang HY, et al. Remimazolam anaphylaxis during induction of general anesthesia confirmed by provocation test-A case report and literature review. Medicina. 2023;59: 1915.","journal-title":"Medicina"},{"key":"6187_CR10","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/j.bja.2022.07.047","volume":"129","author":"KM Kim","year":"2022","unstructured":"Kim KM, Lee H, Bang J-Y, Choi B-M, Noh G-J. Anaphylaxis following remimazolam administration during induction of anesthesia. Br J Anaesth. 2022;129:e122\u20134.","journal-title":"Br J Anaesth"},{"key":"6187_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100472","volume":"13","author":"V Cardona","year":"2020","unstructured":"Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Org J. 2020;13: 100472.","journal-title":"World Allergy Org J"},{"key":"6187_CR12","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.jaip.2024.06.036","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang J, Lieberman JA, Wallace DV, Waserman S, Golden DBK. Anaphylaxis in practice: a guide to the 2023 practice parameter update. J Allergy Clin Immunol Pract. 2024;12:2325\u201336.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06187-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:42:43Z","timestamp":1786592563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06187-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6187"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06187-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report was approved by the Biomedical Ethics Committee of Mianyang Central Hospital (Approval No. S20260399-01). Written informed consent for publication was obtained from the patient.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report, accompanying tables\/figures, and all relevant clinical data. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"463"}}